SLC6A3 and Parkinson disease: Moreover, the noninvasive neuroreceptor PET imaging also allowed the in vivo evaluation of the aberrant nigrostriatal dopamine transporter (DAT) function, which was one of the most prominent and sensitive biomarkers in the early stage of PD [12].